193 related articles for article (PubMed ID: 28361969)
1. HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.
Tsuji S; Washimi K; Kageyama T; Yamashita M; Yoshihara M; Matsuura R; Yokose T; Kameda Y; Hayashi H; Morohoshi T; Tsuura Y; Yusa T; Sato T; Togayachi A; Narimatsu H; Nagasaki T; Nakamoto K; Moriwaki Y; Misawa H; Hiroshima K; Miyagi Y; Imai K
Sci Rep; 2017 Mar; 7():45768. PubMed ID: 28361969
[TBL] [Abstract][Full Text] [Related]
2. Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.
Matsuura R; Kaji H; Tomioka A; Sato T; Narimatsu H; Moriwaki Y; Misawa H; Imai K; Tsuji S
Sci Rep; 2018 Sep; 8(1):14251. PubMed ID: 30250045
[TBL] [Abstract][Full Text] [Related]
3. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
4. Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma.
Tsuji S; Imai K
Proc Jpn Acad Ser B Phys Biol Sci; 2023; 99(2):39-47. PubMed ID: 36775341
[TBL] [Abstract][Full Text] [Related]
5. HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells.
Fujii T; Itami H; Uchiyama T; Morita K; Nakai T; Hatakeyama K; Sugimoto A; Shimada K; Tsuji S; Ohbayashi C
Biochem Biophys Res Commun; 2020 Jun; 526(4):927-933. PubMed ID: 32284171
[TBL] [Abstract][Full Text] [Related]
6. Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
Kouro T; Higashijima N; Horaguchi S; Mano Y; Kasajima R; Xiang H; Fujimoto Y; Kishi H; Hamana H; Hoshino D; Himuro H; Matsuura R; Tsuji S; Imai K; Sasada T
Int J Cancer; 2024 May; 154(10):1828-1841. PubMed ID: 38212893
[TBL] [Abstract][Full Text] [Related]
7. Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases.
Churg A; Naso JR
Histopathology; 2023 Feb; 82(3):385-392. PubMed ID: 36008876
[TBL] [Abstract][Full Text] [Related]
8. Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.
Hiroshima K; Wu D; Koh E; Sekine Y; Ozaki D; Yusa T; Nakazawa T; Tsuji S; Miyagi Y; Walts AE; Marchevsky AM; Husain AN; Imai K
Pathol Int; 2021 Sep; 71(9):604-613. PubMed ID: 34240508
[TBL] [Abstract][Full Text] [Related]
9. Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.
Nakayama K; Seike M; Noro R; Takeuchi S; Matsuda K; Kunugi S; Kubota K; Gemma A
Anticancer Res; 2019 Feb; 39(2):627-633. PubMed ID: 30711938
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
11. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN
Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555
[TBL] [Abstract][Full Text] [Related]
13. Correspondence: SPARC, HEG1, and the Diagnosis of Epithelioid Mesothelioma.
Churg A; Naso JR
Am J Surg Pathol; 2024 May; 48(5):632. PubMed ID: 38223954
[No Abstract] [Full Text] [Related]
14. Immunohistochemistry in the diagnosis of malignant mesothelioma.
Pfaltz M; Odermatt B; Christen B; Rüttner JR
Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
Dejmek A; Hjerpe A
Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma.
Stahel RA; O'Hara CJ; Waibel R; Martin A
Int J Cancer; 1988 Feb; 41(2):218-23. PubMed ID: 3276635
[TBL] [Abstract][Full Text] [Related]
17. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
[TBL] [Abstract][Full Text] [Related]
18. About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.
Mlika M; Zorgati M; BenKhelil M; Mezni FE
J Immunoassay Immunochem; 2019; 40(3):269-282. PubMed ID: 30810450
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in malignant pleural mesothelioma.
Davidson B
Hum Pathol; 2015 Jun; 46(6):789-804. PubMed ID: 25824607
[TBL] [Abstract][Full Text] [Related]
20. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
Pu RT; Pang Y; Michael CW
Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
